WallStSmart

Cantaloupe Inc (CTLP)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cantaloupe Inc generates 23% more annual revenue ($317.56M vs $258.90M). CTLP leads profitability with a 17.3% profit margin vs -15.5%. CTLP earns a higher WallStSmart Score of 59/100 (C).

CTLP

Buy

59

out of 100

Grade: C

Growth: 8.0Profit: 7.0Value: 6.7Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CTLPUndervalued (+80.8%)

Margin of Safety

+80.8%

Fair Value

$54.52

Current Price

$10.92

$43.60 discount

UndervaluedFair: $54.52Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTLP3 strengths · Avg: 9.0/10
EPS GrowthGrowth
201.7%10/10

Earnings expanding 201.7% YoY

Return on EquityProfitability
24.5%9/10

Every $100 of equity generates 25 in profit

P/E RatioValuation
14.8x8/10

Attractively priced relative to earnings

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

CTLP3 concerns · Avg: 2.3/10
Market CapQuality
$795.44M3/10

Smaller company, higher risk/reward

PEG RatioValuation
8.692/10

Expensive relative to growth rate

Free Cash FlowQuality
$-614,0002/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : CTLP

The strongest argument for CTLP centers on EPS Growth, Return on Equity, P/E Ratio. Profitability is solid with margins at 17.3% and operating margin at 6.9%.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : CTLP

The primary concerns for CTLP are Market Cap, PEG Ratio, Free Cash Flow.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

CTLP profiles as a mature stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CTLP scores higher overall (59/100 vs 41/100), backed by strong 17.3% margins. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cantaloupe Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Cantaloupe, Inc., a software and payments company, provides technology solutions for the underserved retail market. The company is headquartered in Malvern, Pennsylvania.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?